A detailed history of Vanguard Group Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,398,298 shares of LYEL stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,398,298
Previous 13,388,425 0.07%
Holding current value
$11.5 Million
Previous $29.9 Million 34.93%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.3 - $3.01 $12,834 - $29,717
9,873 Added 0.07%
13,398,298 $19.4 Million
Q1 2024

May 10, 2024

SELL
$1.71 - $3.07 $368,679 - $661,898
-215,602 Reduced 1.58%
13,388,425 $29.9 Million
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $4.59 Million - $7.77 Million
-3,305,693 Reduced 19.55%
13,604,027 $26.4 Million
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $47,077 - $108,764
32,467 Added 0.19%
16,909,720 $24.9 Million
Q2 2023

Aug 14, 2023

BUY
$1.89 - $3.86 $7.78 Million - $15.9 Million
4,118,130 Added 32.28%
16,877,253 $53.7 Million
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $330,749 - $601,056
167,893 Added 1.33%
12,759,123 $30.1 Million
Q4 2022

Feb 10, 2023

BUY
$2.78 - $8.09 $513,235 - $1.49 Million
184,617 Added 1.49%
12,591,230 $43.7 Million
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $9.84 Million - $14.7 Million
1,776,617 Added 16.71%
12,406,613 $90.9 Million
Q2 2022

Aug 12, 2022

BUY
$3.68 - $6.8 $6.81 Million - $12.6 Million
1,851,294 Added 21.09%
10,629,996 $69.3 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.7 $33.5 Million - $51.1 Million
6,635,614 Added 309.63%
8,778,702 $44.3 Million
Q4 2021

Feb 14, 2022

SELL
$7.13 - $15.19 $497,182 - $1.06 Million
-69,731 Reduced 3.15%
2,143,088 $16.6 Million
Q3 2021

Nov 12, 2021

BUY
$11.0 - $17.95 $5.1 Million - $8.32 Million
463,441 Added 26.49%
2,212,819 $32.7 Million
Q2 2021

Aug 13, 2021

BUY
$15.99 - $16.89 $28 Million - $29.5 Million
1,749,378 New
1,749,378 $28.4 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $213M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.